NCT00003473View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 1996

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Mixed Gliomas
Interventions
DRUG

Atengenal

Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).

DRUG

Astugenal

Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER